Collegium Pharmaceutical Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | +1,564.3% | +884.7% | +5.8% | +4.5% | -10.7% | +67.6% | +22.2% | +11.4% | +23.6% | |
| – | – | +24.6% | +1,118.3% | +6,284.5% | +16.9% | -32.8% | -3.0% | +101.5% | -5.4% | +5.6% | +24.9% | |
| – | – | – | +1,627.7% | +343.3% | -10.2% | +74.5% | -16.2% | +39.1% | +55.7% | +15.7% | +22.8% | |
| – | -46.7% | +87.4% | -42.7% | +1.0% | +19.4% | -5.5% | -3.3% | -57.9% | -100.0% | – | – | |
| – | +599.6% | +325.9% | +15.0% | +36.7% | -8.1% | -6.9% | +5.8% | +39.8% | -5.4% | +13.5% | +65.3% | |
| – | +52.3% | +255.2% | +6.0% | +33.6% | -6.4% | -2.5% | +7.6% | +32.5% | -9.6% | +30.3% | +33.1% | |
| – | – | – | – | – | – | – | -68.7% | +89.0% | +401.1% | +1.8% | +10.1% | |
| – | +74.2% | -78.6% | +519.1% | +3,358.8% | -95.5% | +3,077.3% | -27.2% | +200.8% | +31.8% | -11.2% | +11.3% | |
| – | – | – | – | – | – | – | -112.2% | – | – | +30.2% | -6.0% | |
| – | -136.1% | – | -1,338.3% | – | – | – | -9,123.0% | – | – | +6.5% | +1.3% | |
| – | – | – | – | – | – | – | +167.3% | -135.0% | – | +43.7% | -9.1% | |
| – | – | – | – | – | -106.9% | – | -26.7% | +100.2% | +77.9% | +10.8% | +17.4% |
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.